Notice of Closed Meeting, 75286-75287 [2023-24242]
Download as PDF
<![CDATA[
75286
Federal Register / Vol. 88, No. 211 / Thursday, November 2, 2023 / Notices
Æ KQ 2b. Do outcomes vary by patient/
client (as well as parent) or clinical or
organizational characteristics including the
nature, extent, and timing of exposure (e.g.,
recent or ongoing vs. prior exposure)?
PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)
PICOTS
Population ............................
Intervention ..........................
Comparator ..........................
Outcome ...............................
Timing ..................................
Setting ..................................
KQ1
Adults 18 years and older, regardless of trauma exposure.
1b. Patient/client and clinical characteristics including
type, time since, and duration of trauma exposure;
gender; race/ethnicity; age; clinical condition; or disorder (e.g., anxiety, depression, substance use).
TIC models/components of care (e.g., education and
training of providers about trauma, screening patients/clients for trauma exposure using ACEs or
other tools, screening for symptoms, delivering pointof-care interventions, referring patients/clients for various forms of additional assessment and treatment
for indicated needs).
1a. single or multi-component, individual or group, targeting organizations, providers, patients/clients, caregivers, or a combination, training, screening.
No TIC model of care/usual or routine care (CAU) ........
Other TIC model or component(s) of care, evidencebased therapies for trauma-related conditions (e.g.,
prolonged exposure, cognitive processing therapy) or
approaches (e.g., Collaborative Care).
Trauma-Specific: Additional or repeat trauma exposure
from the point-of-care in the course of care/service
delivery (e.g., retraumatization).
Process outcomes: Health care outcomes/utilization/referral, provider burnout/mental health.
Organizational/practice/systems outcomes: Intake and
referral processes (e.g., wait times), disseminated
policies, trainings, staffing (e.g., scribes), administrative requirements, access to treatment, workforce diversity.
Patient/client-centered outcomes: Physical and mental
health outcomes, functioning, clinical improvement,
patient/client engagement, trust, comfort or satisfaction, and strengths-based outcomes (e.g., quality of
life).
Harms: Includes displacement of evidence based care
(e.g., screening for anxiety, depression, substance
use, suicide risk), increase in patient/client aggression or other behavioral misconduct.
Any ..................................................................................
Routine or emergency healthcare in any setting that
provides human or social services, including in nontraditional settings (e.g., HIV clinics providing behavioral health care).
Dated: October 27, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023–24214 Filed 11–1–23; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
VerDate Sep<11>2014
16:32 Nov 01, 2023
KQ2
Jkt 262001
Youth <18 years, regardless of trauma exposure.
2b. Patient/client and clinical characteristics including
type, time since, and duration of trauma exposure;
gender; race/ethnicity; age; clinical condition; or disorder, (e.g., anxiety, depression, ADHD, conduct disorder, substance use).
TIC models/components of care (e.g., education and
training of providers about trauma, screening patients/clients for trauma exposure using ACEs or
other tools, screening for symptoms, delivering point
of care interventions, referring patients/clients for various forms of additional assessment and treatment
for indicated needs).
2a. single or multi-component, individual or group, targeting organizations, providers, patients/clients, caregivers, or a combination, training, screening.
No TIC model of care/usual or routine care (CAU).
Other TIC model or component(s) of care, evidencebased therapies for trauma-related conditions (e.g.,
trauma-focused CBT) or approaches (e.g., Collaborative Care).
Trauma-Specific: Additional or repeat trauma exposure
from the point-of-care in the course of care/service
delivery (e.g., retraumatization).
Process outcomes: Healthcare outcomes/utilization/referral, provider outcomes burnout/mental health.
Organizational/practice/systems outcomes: Intake and
referral processes (e.g., wait times), disseminated
policies, trainings, staffing (e.g., scribes), administrative requirements, access to treatment, workforce diversity, anti-racism principles.
Patient/client-centered outcomes: Physical and mental
health outcomes, functioning, clinical improvement,
patient/client engagement, trust, comfort or satisfaction, and strengths-based outcomes (e.g., quality of
life).
Harms: Includes displacement of evidence based care
(e.g., screening for developmental milestones,
ADHD, depression, anxiety, suicide risk, substance
use), increase in patient/client aggression or other
behavioral misconduct.
Any.
Routine or emergency healthcare in any setting that
provides human or social services, including in nontraditional settings (e.g., school-based clinics providing behavioral health care).
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
TS24–010, Identify and Evaluate
Potential Risk Factors for Amyotrophic
Lateral Sclerosis (ALS).
Date: April 9, 2024.
Time: 8:30 a.m.–5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Mikel L. Walters, Ph.D., Scientific
Review Officer, National Center for
E:\FR\FM\02NON1.SGM
02NON1
Federal Register / Vol. 88, No. 211 / Thursday, November 2, 2023 / Notices
Injury Prevention and Control, Centers
for Disease Control and Prevention,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341.
Telephone: (404) 639–0913; Email:
MWalters@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
and Prevention, 4770 Buford Highway
NE, Mailstop F–63, Atlanta, Georgia
30341. Telephone: (770) 488–1504;
Email: CGentles@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
CE24–030, Research Grants for
Preventing Violence and Violence
Related Injury (R01).
Dates: April 2–3, 2024.
Times: 8:30 a.m.–5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Carlisha Gentles, Pharm.D., B.C.P.S.,
C.D.C.E.S., Scientific Review Officer,
National Center for Injury Prevention
and Control, Centers for Disease Control
Jkt 262001
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–24239 Filed 11–1–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
16:32 Nov 01, 2023
Georgia 30341. Telephone: (404) 639–
0913; Email: MWalters@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2023–24241 Filed 11–1–23; 8:45 am]
[FR Doc. 2023–24242 Filed 11–1–23; 8:45 am]
VerDate Sep<11>2014
75287
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
CE22–003, Rigorously Evaluating
Programs and Policies to Prevent Child
Sexual Abuse (CSA).
Date: April 11, 2024.
Time: 8:30 a.m.–5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Mikel L. Walters, Ph.D., Scientific
Review Officer, National Center for
Injury Prevention and Control, Centers
for Disease and Prevention, 4770 Buford
Highway NE, Mailstop S106–9, Atlanta,
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
CE24–012, Rigorous Evaluation of
Policy-Level Interventions to Prevent
Overdose.
Date: March 26, 2024.
Time: 8:30 a.m.–5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Aisha L. Wilkes, M.P.H., Scientific
Review Officer, National Center for
Injury Prevention and Control, Centers
for Disease Control and Prevention,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341.
Telephone (404) 639–6473; Email:
AWilkes@cdc.gov.
E:\FR\FM\02NON1.SGM
02NON1
]]>Agencies
[Federal Register Volume 88, Number 211 (Thursday, November 2, 2023)]
[Notices]
[Pages 75286-75287]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24242]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the
following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended, and the Determination of the Director, Office of
Strategic Business Initiatives, Office of the Chief Operating Officer,
CDC, pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)-TS24-010, Identify and Evaluate
Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS).
Date: April 9, 2024.
Time: 8:30 a.m.-5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Mikel L. Walters, Ph.D.,
Scientific Review Officer, National Center for
[[Page 75287]]
Injury Prevention and Control, Centers for Disease Control and
Prevention, 4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia
30341. Telephone: (404) 639-0913; Email: [email protected].
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-24242 Filed 11-1-23; 8:45 am]
BILLING CODE 4163-18-P
